Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

11 de mayo de 2026 actualizado por: Sinovac Life Sciences Co., Ltd.

A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants

A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).

The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

A phase III clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Philippines infants aged approximately 2 months (42 to 89 days).

The trial is a randomized, double-blind, active controlled study. The objective of this study is to evaluate the immunogenicity and safety of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Prevenar 13™ manufactured by Pfizer.

About 500 infants aged approximately 2 months (42 to 89 days) will be enrolled. Participants will be randomized in 1:1 ratio to the test group and control group.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

500

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Cavite
      • Imus, Cavite, Filipinas
        • Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  1. Health infants aged approximately 2 months (42 to 89 days)
  2. Have a parent/legal guardian who has provided written informed consent after being fully informed about the study.
  3. Be able to provide the vaccination records since birth.
  4. The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).

Exclusion Criteria:

  1. Previous vaccination of any licensed or investigational pneumococcal vaccine, or planned receipt during the study participation;
  2. Previous vaccination of vaccines containing the component of diphtheria, tetanus, pertussis, poliomyelitis, and/or Hib vaccine.
  3. Previous receipt of ≥2 doses of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old.
  4. History of severe adverse reaction to previous vaccinations and/or serious allergic reactions (eg, anaphylaxis) to any vaccine component.
  5. History of any laboratory confirmed pneumococcal bacterial pneumonia or invasive pneumococcal diseases caused by S pneumoniae.
  6. Premature infants (born before week 37 of gestation).
  7. Severe congenital malformations, developmental disorders, clinically significant genetic defects, malnutrition.
  8. Autoimmune diseases or immunodeficiency/immunosuppression.
  9. Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.
  10. Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).
  11. Received immunosuppressive for ≥14 days (e.g., prednisone equivalent of ≥2 mg/kg), or cytotoxic drug before enrollment, or plans to receive these treatments during the study participation.
  12. Received blood products before investigational vaccine inoculation, or plan to receive these treatments during study participation.
  13. Received other investigational drugs/vaccines before enrollment, or plan to receive investigational drugs/vaccines during study participation.
  14. Received live attenuated vaccines or nucleic-acid vaccines within 14 days before enrollment.
  15. Received subunit or inactivated vaccines within 7 days before enrollment.
  16. Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.
  17. Axillary temperature ≥ 37.5°C before enrollment.
  18. Any other factors judged by the investigators as unsuitable for participation.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Sinovac PCV 13
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
Comparador activo: Prevenar 13™
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
Periodo de tiempo: 30 days after dose 2.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 2.
30 days after dose 2.
Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.
Periodo de tiempo: 30 days after dose 2
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 2.
30 days after dose 2

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidencia de reacciones adversas
Periodo de tiempo: 0-7 días después de cada dosis
Incidencia de reacciones adversas dentro de los 7 días posteriores a cada dosis
0-7 días después de cada dosis
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
Periodo de tiempo: 30 days after dose 3.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 3.
30 days after dose 3.
Geometric mean concentrations (GMCs ) of serotype-specific IgG antibody.
Periodo de tiempo: 30 days after dose 3.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 3.
30 days after dose 3.
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL
Periodo de tiempo: 30 days after dose 2
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 2
30 days after dose 2
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL .
Periodo de tiempo: 30 days after dose 3
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 3.
30 days after dose 3
GMC fold increases (GMFRs) in IgG antibody concentrations.
Periodo de tiempo: From before dose 3 to 30 days after dose 3
GMC fold increases (GMFRs) in IgG antibody concentrations from before dose 3 to 30 days after dose 3.
From before dose 3 to 30 days after dose 3
Percentage of participants with serotype-specific opsonophagocytosis assay (OPA) antibody titers ≥1:8
Periodo de tiempo: 30 days after the dose 2.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 2.
30 days after the dose 2.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8.
Periodo de tiempo: 30 days after the dose 3.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 3.
30 days after the dose 3.
Geometric mean titers (GMTs) of serotype-specific OPA antibody.
Periodo de tiempo: 30 days after dose 2.
Geometric mean titers (GMTs) of serotype-specific OPA antibody 30 days after dose 2.
30 days after dose 2.
GMTs of serotype-specific OPA antibody .
Periodo de tiempo: 30 days after dose 3.
GMTs of serotype-specific OPA antibody at 30 days after dose 3.
30 days after dose 3.
GMT fold rises (GMFRs) in OPA titers.
Periodo de tiempo: From before dose 3 to 30 days after dose 3.
GMT fold rises (GMFRs) in OPA titers from before dose 3 to 30 days after dose 3.
From before dose 3 to 30 days after dose 3.
Incidence of adverse reactions
Periodo de tiempo: 0-30 days after each dose.
Incidence of adverse reactions within 30 days after each dose.
0-30 days after each dose.
Incidence of serious adverse events(SAEs)
Periodo de tiempo: From dose 1 to 30 days after dose 3
Incidence of SAEs from dose 1 to 30 days after dose 3
From dose 1 to 30 days after dose 3
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL
Periodo de tiempo: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL
Periodo de tiempo: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration
Periodo de tiempo: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration ≥ the observed anti-pertussis antibody concentration achieved by 95% of Prevenar 13™ recipients at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL
Periodo de tiempo: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL
Periodo de tiempo: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8
Periodo de tiempo: 30 days after dose 3 of IPV
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8 measured at 30 days after dose 3 of IPV
30 days after dose 3 of IPV

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Edison Alberto, Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de mayo de 2026

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de mayo de 2026

Publicado por primera vez (Actual)

18 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • PRO-PCV13-3003

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir